肺癌。9：肺癌的分子生物学：临床意义。
Lung cancer. 9: Molecular biology of lung cancer: clinical implications.
作者信息
Fong K M, Sekido Y, Gazdar A F, Minna J D
机构信息
The Prince Charles Hospital, Rode Road, Chermside, Brisbane 4032, Australia.
出版信息
Thorax. 2003 Oct;58(10):892-900. doi: 10.1136/thorax.58.10.892.
Abstract
It has been hypothesised that clinically evident lung cancers have accumulated many different genetic or epigenetic abnormalities in oncogenes and/or tumour suppressor genes. This notion has important clinical ramifications. Recent developments in our knowledge of the molecular biology of lung cancer are reviewed, with particular reference to genetic abnormalities in tumour suppressor gene inactivation and overactivity of growth promoting oncogenes. These changes lead to the "hallmarks of lung cancer". These hallmarks are the new rational targets for early detection, prevention, and treatment of lung cancer.
摘要
据推测，临床上可见的肺癌在癌基因和/或肿瘤抑制基因中积累了许多不同的遗传或表观遗传异常。这一观点具有重要的临床意义。本文综述了我们对肺癌分子生物学认识的最新进展，特别提及肿瘤抑制基因失活中的遗传异常以及促生长癌基因的过度激活。这些变化导致了“肺癌的特征”。这些特征是肺癌早期检测、预防和治疗的新合理靶点。
相似文献
1
Lung cancer. 9: Molecular biology of lung cancer: clinical implications.肺癌。9：肺癌的分子生物学：临床意义。
Thorax. 2003 Oct;58(10):892-900. doi: 10.1136/thorax.58.10.892.
2
Clinical implications of molecular abnormalities in lung cancer.肺癌分子异常的临床意义
Cancer Treat Rev. 1998 Oct;24(5):317-30. doi: 10.1016/s0305-7372(98)90055-x.
3
Genes that regulate metastasis and angiogenesis.调控转移和血管生成的基因。
J Neurooncol. 2000 Oct-Nov;50(1-2):71-87. doi: 10.1023/a:1006466605356.
4
Molecular pathogenesis of lung cancer.肺癌的分子发病机制
J Thorac Cardiovasc Surg. 1999 Dec;118(6):1136-52. doi: 10.1016/S0022-5223(99)70121-2.
5
Molecular pathogenesis of lung cancer.肺癌的分子发病机制
Annu Rev Physiol. 2002;64:681-708. doi: 10.1146/annurev.physiol.64.081501.155828.
6
A translational view of the molecular pathogenesis of lung cancer.肺癌分子发病机制的转化视角。
J Thorac Oncol. 2007 Apr;2(4):327-43. doi: 10.1097/01.JTO.0000263718.69320.4c.
7
Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.胰腺癌的分子生物学；从临床角度看癌基因、肿瘤抑制基因、生长因子及其受体
Cancer Treat Rev. 2000 Feb;26(1):29-52. doi: 10.1053/ctrv.1999.0144.
8
Molecular aspects of neuro-oncology.神经肿瘤学的分子层面
Clin Neurol Neurosurg. 1997 Aug;99(3):184-95. doi: 10.1016/s0303-8467(97)00025-5.
9
Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review.肺癌侵袭和转移的关键分子机制：全面综述。
Crit Rev Oncol Hematol. 2013 Jul;87(1):1-11. doi: 10.1016/j.critrevonc.2012.12.007. Epub 2013 Jan 16.
10
Genetic alterations in human prostate cancer: a review of current literature.人类前列腺癌的基因改变：当前文献综述
Anticancer Res. 2000 May-Jun;20(3B):1905-12.
引用本文的文献
1
Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity.抑癌基因 Clusterin 的失活导致肺癌细胞中 TAK1-NF-κB 信号轴的过度激活，并提示了一个治疗机会。
Theranostics. 2020 Sep 16;10(25):11520-11534. doi: 10.7150/thno.44829. eCollection 2020.
2
Cell Derived Matrix Fibulin-1 Associates With Epidermal Growth Factor Receptor to Inhibit Its Activation, Localization and Function in Lung Cancer Calu-1 Cells.细胞衍生基质纤连蛋白-1与表皮生长因子受体结合以抑制其在肺癌Calu-1细胞中的激活、定位和功能。
Front Cell Dev Biol. 2020 Jul 3;8:522. doi: 10.3389/fcell.2020.00522. eCollection 2020.
3
Polyphenolic compounds from Korean Thunb. induces apoptosis via AKT and caspase cascade activation in A549 cells.来自朝鲜蓟的多酚类化合物通过激活A549细胞中的AKT和半胱天冬酶级联反应诱导细胞凋亡。
Oncol Lett. 2017 Apr;13(4):2521-2530. doi: 10.3892/ol.2017.5771. Epub 2017 Feb 23.
4
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.红菌素A是一种新型的Src靶向化合物，可通过调节Src相关通路来抑制肺癌细胞的进展。
Oncotarget. 2015 Sep 22;6(28):26252-65. doi: 10.18632/oncotarget.4761.
5
CUGBP1 promotes cell proliferation and suppresses apoptosis via down-regulating C/EBPα in human non-small cell lung cancers.CUGBP1通过下调人非小细胞肺癌中的C/EBPα来促进细胞增殖并抑制细胞凋亡。
Med Oncol. 2015 Mar;32(3):82. doi: 10.1007/s12032-015-0544-8. Epub 2015 Feb 21.
6
microRNA-99a is downregulated and promotes proliferation, migration and invasion in non-small cell lung cancer A549 and H1299 cells.微小RNA-99a在非小细胞肺癌A549和H1299细胞中表达下调，并促进细胞增殖、迁移和侵袭。
Oncol Lett. 2015 Mar;9(3):1128-1134. doi: 10.3892/ol.2015.2873. Epub 2015 Jan 14.
7
CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.CIP2A通过AKT信号通路调节人肺癌细胞的增殖。
Oncol Rep. 2014 Oct;32(4):1689-94. doi: 10.3892/or.2014.3375. Epub 2014 Aug 1.
8
Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells.肺癌与浸润性肺组织T细胞、自然杀伤（NK）T样细胞和NK细胞中穿孔素、颗粒酶B和干扰素（IFN）-γ的表达降低有关。
Clin Exp Immunol. 2014 Oct;178(1):79-85. doi: 10.1111/cei.12392.
9
Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.当前 NSCLC 临床情况下癌症疫苗面临的挑战和机遇。
Curr Top Med Chem. 2013;13(20):2551-61. doi: 10.2174/15680266113136660182.
10
Roles of Mir-144-ZFX pathway in growth regulation of non-small-cell lung cancer.Mir-144-ZFX 通路在非小细胞肺癌生长调控中的作用。
PLoS One. 2013 Sep 16;8(9):e74175. doi: 10.1371/journal.pone.0074175. eCollection 2013.
本文引用的文献
1
Molecular pathogenesis of lung cancer.肺癌的分子发病机制
Annu Rev Physiol. 2002;64:681-708. doi: 10.1146/annurev.physiol.64.081501.155828.
2
Cancer statistics, 2002.2002年癌症统计数据。
CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47. doi: 10.3322/canjclin.52.1.23.
3
Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers.既往吸烟者支气管刷检样本中多个基因的异常启动子甲基化
Cancer Res. 2002 Jan 15;62(2):351-5.
4
Novel pharmacological agents in clinical development for solid tumours.用于实体瘤临床开发的新型药理制剂。
Expert Opin Investig Drugs. 2001 Dec;10(12):2059-88. doi: 10.1517/13543784.10.12.2059.
5
Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.5-氮杂-2'-脱氧胞苷增加人肺癌细胞中未甲基化CDKN2D的表达。
Oncogene. 2001 Nov 22;20(53):7787-96. doi: 10.1038/sj.onc.1204970.
6
Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene.Dutt1/Robo1基因靶向缺失小鼠的肺发育不全和支气管增生
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15062-6. doi: 10.1073/pnas.251407098. Epub 2001 Dec 4.
7
Towards a biological staging model for operable non-small cell lung cancer.迈向可手术非小细胞肺癌的生物学分期模型
Lung Cancer. 2001 Dec;34 Suppl 2:S83-9. doi: 10.1016/s0169-5002(01)00352-x.
8
Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis.血管内皮生长因子（VEGF）在非小细胞肺癌（NSCLC）中的表达：与p53基因突变及预后的关系
Lung Cancer. 2001 Dec;34 Suppl 2:S59-64. doi: 10.1016/s0169-5002(01)00346-4.
9
Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B.重新表达3p21.3候选抑癌基因SEMA3B后对肺癌细胞生长的抑制及凋亡诱导作用。
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13954-9. doi: 10.1073/pnas.231490898.
10
Diversity of gene expression in adenocarcinoma of the lung.肺腺癌中基因表达的多样性。
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9. doi: 10.1073/pnas.241500798. Epub 2001 Nov 13.
Zotero 插件